Table 1.
Comparison of clinicopathological characteristics of 843 HER2-positive patients
| Factors | Without trastuzumab | With trastuzumab | p-value | |
|---|---|---|---|---|
| Group 1 n(%) |
Group 2 n(%) |
Group 3 n(%) |
||
| Age (year) | ||||
| ≤ 40 | 31 (12.2) | 76 (25.9) | 44 (15.0) | < 0.001 |
| > 40 | 224 (87.8) | 218 (74.1) | 250 (85.0) | |
| T stage | ||||
| T1 | 51 (20.0) | 70 (23.8) | 64 (21.8) | 0.044 |
| T2 | 172 (67.5) | 172 (58.5) | 200 (68.0) | |
| T3–4 | 32 (12.5) | 52 (17.7) | 30 (10.2) | |
| N stage | ||||
| pN0 | 144 (56.5) | 162 (55.1) | 152 (51.7) | 0.217 |
| pN1 | 76 (29.8) | 78 (26.5) | 79 (26.9) | |
| pN2–3 | 35 (13.7) | 54 (18.4) | 63 (21.4) | |
| Histological grade | ||||
| 1~2 | 198 (77.6) | 246 (83.7) | 242 (82.3) | 0.171 |
| 3 | 57 (22.4) | 48 (16.3) | 52 (17.7) | |
| HR | ||||
| Negative | 145 (56.9) | 164 (55.8) | 164 (55.8) | 0.957 |
| Positive | 110 (43.1) | 130 (44.2) | 130 (44.2) | |
| Ki67 (%) | ||||
| < 30 | 67 (52.8) | 134 (45.6) | 132 (44.9) | 0.187 |
| ≥ 30 | 60 (47.2) | 160 (54.4) | 162 (55.1) | |
| NC | ||||
| No | 117 (45.9) | 128 (43.5) | 130 (44.2) | 0.853 |
| Yes | 138 (54.1) | 166 (56.5) | 164 (55.8) | |
| Total | 255 (100.0) | 294 (100.0) | 294 (100.0) | |
Group 1 contained patients without trastuzuamb treatment, group 2 contained patients with trastuzuamb and low pre-NLR value, and group 3 contained patients with trastuzuamb and high pre-NLR value. Statistically significant factors are in bold font. NLR, neutrophil/lymphocyte ratio; HR, hormone receptor; NC, neoadjuvant chemotherapy